## Gabriela F De Larrañaga

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3605990/publications.pdf

Version: 2024-02-01

43 papers 774 citations

758635 12 h-index 27 g-index

44 all docs

44 docs citations

44 times ranked 1217 citing authors

#	Article	IF	CITATIONS
1	Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome. Lupus, 2022, 31, 354-362.	0.8	5
2	A focus on the roles of histones in health and diseases. Clinical Biochemistry, 2021, 94, 12-19.	0.8	11
3	Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine. Lupus, 2020, 29, 1736-1742.	0.8	9
4	A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome. Immunologic Research, 2019, 67, 478-485.	1.3	11
5	Trombofilia hereditaria y pérdidas de embarazo. Estudio de una cohorte de Argentina. Medicina ClÃnica, 2019, 152, 249-254.	0.3	5
6	Maternal carriers of the ANXA5 M2 haplotype are exposed to a greater risk for placenta-mediated pregnancy complications. Journal of Assisted Reproduction and Genetics, 2018, 35, 921-928.	1.2	11
7	What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?. Immunologic Research, 2018, 66, 577-583.	1.3	6
8	Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus, 2017, 26, 983-988.	0.8	48
9	Decreased Levels of Circulatig Protein S in Patients with Active Crohn's Disease. Gastroenterology, 2017, 152, S612.	0.6	0
10	Effect of gene–gene and gene–environment interactions associated with antituberculosis drug-induced hepatotoxicity. Pharmacogenetics and Genomics, 2017, 27, 363-371.	0.7	12
11	The â^308 G/A polymorphism in the tumor necrosis factor-α gene is not associated with development and progression of rheumatoid arthritis in Argentinean patients. International Journal of Rheumatic Diseases, 2016, 19, 476-481.	0.9	7
12	tagSNP rs1495741 as a useful molecular marker to predict antituberculosis drug-induced hepatotoxicity. Pharmacogenetics and Genomics, 2016, 26, 357-361.	0.7	7
13	Q222R polymorphism in the DNAse I gene is not associated with susceptibility to rheumatoid arthritis or to disease course in an Argentine patient cohort. Egyptian Rheumatologist, 2016, 38, 289-293.	0.5	1
14	D-Dimer as a prognostic marker of morbidity and mortality among HIV patients: a call for attention. Infectious Diseases, 2016, 48, 860-861.	1.4	3
15	The $\hat{a}^2518\hat{A}/G$ polymorphism in the monocyte chemoattractant protein 1 gene (MCP-1) is associated with an increased risk of rheumatoid arthritis in Argentine patients. Clinical Rheumatology, 2016, 35, 3057-3061.	1.0	8
16	Paternal factor V Leiden and recurrent pregnancy loss: a new concept behind fetal genetics?: reply. Journal of Thrombosis and Haemostasis, 2014, 12, 1759-1760.	1.9	2
17	Paternal factor V Leiden and recurrent pregnancy loss: a new concept behind fetal genetics?. Journal of Thrombosis and Haemostasis, 2014, 12, 666-669.	1.9	15
18	Neutrophil Extracellular Traps in Sepsis. Shock, 2014, 42, 286-294.	1.0	134

#	Article	IF	CITATIONS
19	4G/5G plasminogen activator inhibitor-1 and â^308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis. Clinical and Experimental Medicine, 2014, 14, 83-89.	1.9	7
20	Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 323-328.	1.4	57
21	Role of -675 4G/5G in the Plasminogen Activator Inhibitor-1 Gene and -308G/A Tumor Necrosis Factor- $\hat{l}\pm$ Gene Polymorphisms in Obese Argentinean Patients. Genetic Testing and Molecular Biomarkers, 2012, 16, 372-375.	0.3	3
22	The -2518 A/G polymorphism in the monocyte chemoattractant protein 1 gene is associated with the risk of developing systemic lupus erythematosus in Argentinean patients: a multicenter study. European Cytokine Network, 2012, 23, 7-11.	1.1	9
23	Biomarkers in sepsis at time zero: intensive care unit scores, plasma measurements and polymorphisms in Argentina. Journal of Infection in Developing Countries, 2012, 6, 555-562.	0.5	17
24	The distribution of allelic and genotypic frequencies of N-Acetyltransferase-2 variants in an Argentine population. Journal of Infection in Developing Countries, 2012, 6, 671-674.	0.5	10
25	Antiâ€Î²2glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal model. Journal of Thrombosis and Haemostasis, 2011, 9, 859-861.	1.9	13
26	Relationship between 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene and obesity in Argentinian Hispanic adults. Blood Coagulation and Fibrinolysis, 2010, 21, 196-198.	0.5	1
27	Role of 4G/5G promoter polymorphism of Plasminogen Activator Inhibitor-1 (PAI-1) gene in outcome of sepsis. Thrombosis Research, 2010, 125, 367-369.	0.8	11
28	Thrombophilia in Human Immunodeficiency Virusâ€"Infected Patients with Osteonecrosis: Is There a Real Connection? The First Case-Control Study. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 340-347.	0.7	13
29	Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 319-324.	0.7	11
30	The range of normal values of liver enzymes in the era of metabolic syndrome: the need for a redefinition. European Journal of Gastroenterology and Hepatology, 2008, 20, 589-591.	0.8	2
31	Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV–HCV–coinfected patients under highly active antiretroviral treatment. European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25, 98-103.	1.3	32
32	Soluble thrombomodulin levels among women with a history of recurrent pregnancy loss, with or without antiphospholipid antibodies. Blood Coagulation and Fibrinolysis, 2005, 16, 31-35.	0.5	4
33	Catastrophic antiphospholipid syndrome and Kikuchi-Fujimoto disease: the first case reported. Lupus, 2005, 14, 967-969.	0.8	10
34	Insulin resistance status is an important determinant of PAI-1 levels in HIV-infected patients, independently of the lipid profile. Journal of Thrombosis and Haemostasis, 2004, 2, 532-534.	1.9	9
35	Association between the acquired free protein S deficiency in HIV-infected patients with the lipid profile levels. Journal of Thrombosis and Haemostasis, 2004, 2, 1195-1197.	1.9	3
36	Relationship between hepatic enzymes and insulin resistance syndrome markers in HIV with lipodystrophy. Hepatology, 2004, 40, 1475-1476.	3.6	2

#	Article	IF	CITATIONS
37	Antibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodies. Journal of Thrombosis and Haemostasis, 2003, 1, 2250-2251.	1.9	8
38	Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thrombosis Research, 2003, 110, 93-98.	0.8	44
39	Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagulation and Fibrinolysis, 2003, 14, 15-18.	0.5	60
40	Activated protein C resistance in patients with arterial ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 2001, 10, 128-131.	0.7	7
41	High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus, 2000, 9, 594-600.	0.8	65
42	Acquired Hypoprothrombinemia Related to High Titres of Antiprotein-phospholipid Antibodies. Thrombosis and Haemostasis, 1999, 81, 317-318.	1.8	5
43	Different Types of Antiphospholipid Antibodies in AIDS. Thrombosis Research, 1999, 96, 19-25.	0.8	68